Ford Alfred J Jr sold $643K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 27,632 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.25 ($22.61–$23.90, $0.64M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 3, 2026, 11:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest disclosed fact is the CCO’s open-market sale details (shares, price range, total value, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but there is no accompanying guidance, trial, deal, or regulatory development in the text.

03

What to watch

The trades span multiple days and explicitly state no pre-arranged 10b5-1 plan, which can increase scrutiny, but the article provides no context on motivations or future intent.

Relevance 5/10Novelty 5/10Timing: Filed 2026-08-03, covering sales from 2026-07-30 to 2026-08-03.

Background

The article is an SEC Form 4 insider transaction filing for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CCO Alfred J. Ford Jr sold 27,632 KMTS shares in open-market trades for about $642.5K, with no 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or unusual volume emerges.

Evidence & confidence

The filing is a primary-source Form 4 and quantifies the sale size and timing, but it does not include new operational, financial, or regulatory information.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Minimal, no macro or cross-regional catalyst is described.

Minimal, no international transaction or global regulatory action is mentioned.

Counterpoint

Insider sales can be driven by diversification or tax planning, so the signal may be weaker than the headline implies.

Key entities

  • KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • Alfred J. Ford Jr

    Chief Commercial Officer who sold 27,632 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.